Regenerative medicine company Novadip Biosciences revealed on Tuesday the election of Jeff Abbey as its chief executive officer.

Effective early 2019, Abbey will succeed the outgoing Jean-Francois Pollet.

Since 2002, Abbey has worked with Argos Therapeutics Inc, an immuno-oncology cell therapy company, in multiple positions including president and chief executive officer for the past eight years.

The company's lead programme is an autologous three-dimensional cell therapy that has completed enrolment of a phase I/IIa trial in spinal fusion patients. Its second clinical programme is currently enrolling patients with non-healing bone fractures.